10-Q: Qualigen Secures $41M, Shifts to Crypto Amidst Losses

Qualigen Therapeutics, Inc. reported a significant capital raise of $41 million, primarily for new cryptocurrency treasury operations, despite ongoing operational losses and substantial doubt about its ability to continue as a going concern.

Summary

• Qualigen Therapeutics, Inc. is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer, with lead program QN-302 and preclinical Pan-RAS program.
• The company reported a net loss of $2,037,819 for the three months ended September 30, 2025, and $6,369,407 for the nine months ended September 30, 2025.
• General and administrative expenses increased by $0.8 million (72%) to $1.9 million for the three months ended September 30, 2025, and by $2.5 million (78%) to $5.7 million for the nine months ended September 30, 2025, primarily due to professional fees and investor relations.
• Research and development expenses decreased by $18,000 (15%) to $105,576 for the three months ended September 30, 2025, and by $0.9 million (81%) to $156,558 for the nine months ended September 30, 2025, due to slowed development.
• Cash and cash equivalents significantly increased to $38,777,166 as of September 30, 2025, from $1,174,608 at December 31, 2024, largely due to financing activities.
• The company raised $41.0 million in September 2025 through a Subscription Agreement with investors, including Faraday Future Intelligent Electric Inc., with up to $6.8 million allocated to existing debt and operations, and the balance for cryptocurrency treasury operations.
• An estimated credit loss of $261,000 was recorded on short-term notes receivable from Marizyme, Inc. as of September 30, 2025.
• The company settled a lawsuit with LifeSci Capital LLC for $75,000 in October 2025.
• Management identified material weaknesses in internal control over financial reporting, including insufficient accounting personnel, lack of ITGC access controls, and absence of formalized documentation.

Sentiment

Score: 3

Explanation: While a significant capital raise provides a temporary cash infusion, the underlying operational losses, explicit going concern doubt, slowdown in core therapeutic R&D, and identified material weaknesses in internal controls present a highly challenging outlook. The pivot to cryptocurrency treasury operations introduces substantial speculative risk, making the overall sentiment negative despite the increased cash position.

Positives

• Successfully raised $41.0 million in new capital through a Subscription Agreement, significantly boosting cash reserves to $38.7 million.
• Established new cryptocurrency treasury operations, potentially diversifying future revenue streams.
• Reduced research and development expenses by 81% for the nine months ended September 30, 2025, indicating cost control in therapeutic programs.

Negatives

• Reported recurring net losses, with a net loss of $6,369,407 for the nine months ended September 30, 2025, and an accumulated deficit of $129.4 million.
• Expressed substantial doubt about the ability to continue as a going concern for the next year.
• Slowed development of the QN-302 Phase 1 Study and other therapeutic products due to financial situation.
• Identified material weaknesses in internal control over financial reporting, including insufficient accounting personnel and lack of IT General Controls.
• General and administrative expenses increased significantly by 78% for the nine months ended September 30, 2025, driven by professional fees and investor relations.
• Incurred a credit loss expense of $0.6 million for the three months ended September 30, 2025, related to Marizyme notes receivable.
• The majority of the recent capital raise is earmarked for speculative cryptocurrency treasury operations, not immediate therapeutic R&D.

Risks

• Ability to procure sufficient working capital to continue and complete the development, testing, and launch of prospective drug products.
• Ability to successfully develop any drugs and progress drug candidates through preclinical and clinical development.
• Ability to obtain requisite regulatory approvals for clinical trials and complete them according to projected timelines.
• Likelihood that future clinical trial data will be favorable or confirm improvements over other products.
• Ability to successfully commercialize any drugs.
• Ability to protect intellectual property and the likelihood that patents will issue on in-licensed patent applications.
• Ability to compete in the highly competitive biotechnology industry.
• Uncertainty regarding the new cryptocurrency treasury operations generating revenue.
• Potential adverse effects from global economic conditions, including inflation, slowing growth, rising interest rates, and geopolitical conflicts (Ukraine, Israel).
• Dilution of common stockholders' ownership interests from future equity or convertible debt securities sales.
• Debt financing agreements potentially including covenants limiting specific actions like incurring additional debt or declaring dividends.
• Relinquishing valuable rights to technologies, future revenue streams, or product candidates if additional funds are raised through third-party funding or licensing arrangements.
• Material weaknesses in internal control over financial reporting due to resource constraints, which may not be remediated until additional funding is secured.

Future Outlook

The company expects to continue to incur net losses and negative cash flow from operations, which will challenge its liquidity. While establishing cryptocurrency treasury operations, there are no guarantees it will generate revenue. Management and the board are strategically reviewing plans to best advance the therapeutics pipeline and will ramp up development when properly funded through capital markets or strategic partnerships. The company is evaluating new accounting standards for income tax and expense disaggregation disclosures.

Management Comments

• To experience losses while therapeutic products are still under development is, of course, typical for biotechnology companies.
• Given our financial situation, the company slowed the development of the QN-302 Phase 1 Study beginning in the second quarter of 2024.
• We have also implemented dramatic expense controls in an effort to stem the rate of losses.
• Management and the board are strategically reviewing plans on how to best advance our therapeutics pipeline, and will ramp up development when properly funded through either capital markets or strategic partnerships.
• While we are establishing cryptocurrency treasury operations, it is newly established and there are no guarantees it will generate revenue.
• Due to resource constraints, we are currently unable to employ additional personnel to remediate these material weaknesses (in internal controls). We do not expect remediation until we obtain additional funding to strengthen our accounting department.

Industry Context

The company's continued losses during therapeutic product development are described as 'typical for biotechnology companies,' indicating it operates within an industry where significant upfront investment and prolonged periods of unprofitability are common before commercialization. However, the explicit 'going concern' doubt and the strategic pivot towards cryptocurrency treasury operations, while potentially innovative, diverge from the traditional biotech funding and operational model, introducing a new layer of speculative risk not typically associated with clinical-stage therapeutics. The slowdown in R&D for its core therapeutic programs suggests a struggle to maintain pace with industry peers who are actively advancing their pipelines.

Comparison to Industry Standards

• The company's accumulated deficit of $129.4 million and recurring net losses are common for early-stage biotechnology companies, similar to many small-cap biotechs that require substantial R&D investment before product commercialization.
• The significant reduction in R&D expenses (81% decrease year-over-year for nine months) and the slowdown of the QN-302 Phase 1 study are below industry standards for companies actively pursuing clinical development, suggesting a critical funding shortfall for core operations.
• The pivot to establishing cryptocurrency treasury operations, as seen with the Faraday investment, is an unconventional strategy for a clinical-stage therapeutics company and deviates significantly from typical biotech funding and asset management practices. This introduces a new, high-risk asset class not comparable to standard industry benchmarks.
• The identified material weaknesses in internal control over financial reporting, particularly regarding insufficient accounting personnel and ITGC, are below industry best practices and regulatory expectations for publicly traded companies, potentially impacting financial reporting reliability.

Management Changes

Corporate Governance

Legal Proceedings

• On January 29, 2025, the company was named as a defendant in an action brought by LifeSci Capital LLC in the U.S. District Court for the Southern District of New York, alleging failure to pay $503,483 in connection with offerings.
• On October 9, 2025, the matter was settled out of court, with the company agreeing to pay LifeSci $75,000. An additional accrual of $40,000 was recorded as of September 30, 2025, as $35,000 was already recorded.

Related Party Transactions

• Faraday Future Intelligent Electric Inc. (Lead Investor): Consummated a Subscription Agreement for $41.0 million in September 2025, leading to the issuance of common stock and Series B Convertible Preferred Stock. Also entered into a Lead Investor Agreement for governance changes and treasury reserve policy.
• Alpha Capital Anstalt (Alpha): Issued an 8% Senior Convertible Debenture for $3.3 million in December 2022 (fully settled in 2024). Issued an 8% Convertible Debenture for $550,000 in February 2024 (fully repaid in November 2024). Issued a Secured Convertible Note for $264,000 in April 2025. Also involved in various warrant issuances and repricings.
• Yi Hua Chen (Chen): Alpha assigned an option to Chen in April 2024, leading to the issuance of an 8% Convertible Debenture for $1.1 million (settled in November 2024 by conversion into Series A-2 Preferred Stock). Also issued a liability-classified warrant to Chen.

Stakeholder Impact

• Shareholders: Experienced significant dilution from recent capital raises and warrant issuances. The stock price is highly likely to be influenced by the going concern doubt, operational slowdowns, and the speculative nature of the new cryptocurrency venture. The reverse stock split in November 2024 also impacted share count.
• Employees: Experienced a downsizing of the workforce, leading to a decrease in payroll expenses. Stock-based compensation is part of the compensation structure.
• Customers: The slowdown in the development of therapeutic products (QN-302 Phase 1 Study) may delay potential new treatments for cancer patients.
• Suppliers/Vendors: The company is in arrears on accounts payable to important partners, and a gain on settlement of accounts payable in 2024 suggests past issues with vendor payments.
• Creditors: Repaid approximately $1.1 million of outstanding promissory notes during the nine months ended September 30, 2025, and settled a lawsuit. The reclassification of Marizyme's debt to senior status impacts other creditors of Marizyme.

Next Steps

• Strategically review plans to best advance the therapeutics pipeline.
• Ramp up therapeutic development when properly funded through capital markets or strategic partnerships.
• Evaluate disclosure requirements related to new accounting standards (ASU 2023-09 and ASU 2024-03).
• Obtain additional funding to strengthen the accounting department to remediate material weaknesses in internal controls.
• Monitor relevant events and conditions and update assumptions and allowance for credit losses on Marizyme Notes as necessary.
• Continue to establish and oversee cryptocurrency treasury operations with Bitgo.

Key Dates

Recommendation

Despite a substantial capital raise, the company faces severe fundamental challenges. The explicit 'substantial doubt about the Company's ability to continue as a going concern,' recurring and increasing net losses, and a significant accumulated deficit indicate a precarious financial position. The slowdown in core therapeutic R&D, coupled with identified material weaknesses in internal controls, points to operational and governance deficiencies. The strategic pivot to cryptocurrency treasury operations is highly speculative and introduces significant, unproven risk for a biotech company. For a seasoned investor, these factors collectively suggest a high probability of further value erosion and extreme risk, warranting a strong sell recommendation.

Keywords

Qualigen Therapeutics, QN-302, Pan-RAS, Cancer treatment, Biotechnology, SEC filing, 10-Q, Financial results, Capital raise, Faraday Future Intelligent Electric, Cryptocurrency treasury operations, Going concern, Clinical trials, Drug development, Warrant liabilities, Convertible debt, Marizyme, Internal controls, Risk factors